Empagliflozin reduces brain pathology in Alzheimer's disease and type 2 diabetes

作     者：Carmen Hierro-Bujalance Monica Garcia-Alloza Carmen Hierro-Bujalance;Monica Garcia-Alloza

作者机构：Division of PhysiologySchool of MedicineUniversidad de CadizCadizSpain Instituto de Investigacion e Innovacion en Ciencias Biomedicas de la Provincia de Cadiz(INIBICA)CadizSpain Salus Infirmorum-Universidad de CadizCadizSpain 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2024年第19卷第6期

页      面：1189-1190页

核心收录：

学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学] 

基　　金：supported by Spanish Ministry of Science,Innovation and Universities(grant number PID2020-115499RB-I00/AEI/10.13039/501100011033) Andalusian Consejería de Universidad,Investigación e Innovación(PAIDI2020)(grant P20-00928)(to MGA) 

主　　题：Alzheimer diabetes 

摘      要：Alzheimer s disease(AD)and type 2 diabetes(T2D):More than 55 million people suffer from dementia,and it is expected that over 150 million people will suffer from this disease by *** is the most common type of dementia and while aging remains the main risk factor to suffer it,previous studies have also shown that metabolic disorders,and T2D specifically,are also major contributors(Wang et al.,2012).